UK-371804 HCl Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 447

Clinical Trials

Several clinical trials evaluate interventions across conditions such as colorectal cancer, deep vein thrombosis, SARS-CoV-2 infection with acute kidney injury, and mesenteric traction syndrome. Ranging from Phase 1/Phase 2 to Phase Not Applicable or unassigned studies, these trials are primarily sponsored by academic medical centers and major hospital networks, including the University of Chicago, RenJi Hospital, University of California San Francisco, and Rigshospitalet Denmark. The studies reflect various recruitment statuses, currently encompassing those that are not yet recruiting, actively recruiting, and active but not recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06349590	Not yet recruiting	Colorectal Cancer	University of Chicago	2024-04	Phase 1\|Phase 2
NCT05286710	Recruiting	Deep Vein Thrombosis	RenJi Hospital\|First People''s Hospital of Hangzhou\|The First Affiliated Hospital with Nanjing Medical University\|Affiliated Hospital of Nantong University\|Chengdu University of Traditional Chinese Medicine\|Second Affiliated Hospital of Suzhou University\|Liuzhou Workers Hospital\|Shanghai Pudong New Area People''s Hospital\|Zhejiang University	2022-10-26	Not Applicable
NCT05356767	Recruiting	Pharmacomechanical Thrombolysis\|Deep Vein Thrombosis	Chengdu University of Traditional Chinese Medicine	2022-04-01	--
NCT04705766	Recruiting	SARS-CoV Infection\|Covid19\|Corona Virus Infection\|Acute Kidney Injury\|Kidney Injury	University of California San Francisco\|Rush University Medical Center\|University of Michigan\|University of California	2021-03-01	--
NCT04796493	Active not recruiting	Mesenteric Traction Syndrome	Rigshospitalet Denmark	2021-03-16	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the UK-371804 HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

UK-371804 HCl functions as a potent and selective inhibitor of urokinase-type plasminogen activator with a inhibition constant of 10 nM, directly binding the enzyme to block downstream plasminogen activation and inhibit plasmin-mediated extracellular matrix degradation and cell migration. This targeted disruption of pericellular proteolysis and tissue remodeling attenuates tumor cell invasion and modulates pathological fibrinolytic cascades, providing therapeutic relevance to conditions such as colorectal cancer recurrence and deep vein thrombosis studied in clinical settings.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).